Search Results - Danielle J. Vugts

  • Showing 1 - 19 results of 19
Refine Results
  1. 1
    The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented?

    The new Regulation on clinical trials in relation to radiopharmaceuticals: when and how will it be implemented? by Iván Peñuelas, Daniëlle J. Vugts, Clemens Decristoforo, Philip H. Elsinga

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    State of the art procedures towards reactive [18F]fluoride in PET tracer synthesis

    State of the art procedures towards reactive [18F]fluoride in PET tracer synthesis by Lizeth Y. F. Haveman, Danielle J. Vugts, Albert D. Windhorst

    Published 2023-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    PET Imaging of Microglial Activation—Beyond Targeting TSPO

    PET Imaging of Microglial Activation—Beyond Targeting TSPO by Bieneke Janssen, Danielle J. Vugts, Albert D. Windhorst, Robert H. Mach

    Published 2018-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor

    The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor by Antonia Högnäsbacka, Alex J. Poot, Danielle J. Vugts, Guus A. M. S. van Dongen, Albert D. Windhorst

    Published 2022-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Immuno-PET Imaging of Atherosclerotic Plaques with [<sup>89</sup>Zr]Zr-Anti-CD40 mAb—Proof of Concept

    Immuno-PET Imaging of Atherosclerotic Plaques with [<sup>89</sup>Zr]Zr-Anti-CD40 mAb—Proof of Concept by Kikkie Poels, Maxime Schreurs, Matthijs Jansen, Danielle J. Vugts, Tom T. P. Seijkens, Guus A. M. S. van Dongen, Esther Lutgens, Wissam Beaino

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

    Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. by Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.

    Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing m... by Hasan Alsaid, Tinamarie Skedzielewski, Mary V Rambo, Kristen Hunsinger, Bao Hoang, William Fieles, Edward R Long, James Tunstead, Danielle J Vugts, Matthew Cleveland, Neil Clarke, Christopher Matheny, Beat M Jucker

    Published 2017-01-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology

    Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology by Yvonne W.S. Jauw, C. Willemien Menke-van der Houwen van Oordt, Otto S. Hoekstra, N. Harry Hendrikse, Danielle J. Vugts, Josee M. Zijlstra, Marc C. Huisman, Guus A.M.S. van Dongen

    Published 2016-05-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice

    Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice by Marion Chomet, Maxime Schreurs, Ricardo Vos, Mariska Verlaan, Esther J. Kooijman, Alex J. Poot, Ronald Boellaard, Albert D. Windhorst, Guus AMS van Dongen, Danielle J. Vugts, Marc C. Huisman, Wissam Beaino

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139

    PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139 by Wissam Beaino, Bieneke Janssen, Esther Kooijman, Ricardo Vos, Robert C. Schuit, James O’Brien-Brown, Michael Kassiou, Bert van het Hof, Danielle J. Vugts, Helga E. de Vries, Albert D. Windhorst

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).

    Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). by Pieter J Gaillard, Chantal C M Appeldoorn, Rick Dorland, Joan van Kregten, Francesca Manca, Danielle J Vugts, Bert Windhorst, Guus A M S van Dongen, Helga E de Vries, David Maussang, Olaf van Tellingen

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans

    How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans by Jessica E. Wijngaarden, Amina Ahbari, Johanna E. E. Pouw, Henri N. J. M. Greuter, Idris Bahce, Gerben J. C. Zwezerijnen, Daniëlle J. Vugts, Guus A. M. S. van Dongen, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt, Marc C. Huisman

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET

    Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET by Jessica E. Wijngaarden, Yvonne W. S. Jauw, Gerben J. C. Zwezerijnen, Berlinda J. de Wit-van der Veen, Daniëlle J. Vugts, Josée M. Zijlstra, Guus A. M. S. van Dongen, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt, Marc C. Huisman

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

    Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody by Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans

    The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans by Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom, Marie Davies

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

    Synthesis and preclinical evaluation of [11C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor by Antonia A. Högnäsbacka, Alex J. Poot, Christophe Plisson, Jonas Bergare, David R. Bonsall, Stuart P. McCluskey, Lisa A. Wells, Esther Kooijman, Robert C. Schuit, Mariska Verlaan, Wissam Beaino, Guus A. M. S. van Dongen, Danielle J. Vugts, Charles S. Elmore, Jan Passchier, Albert D. Windhorst

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study

    Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an... by Ashutosh Wechalekar, Gunnar Antoni, Wasfi Al Azzam, Mats Bergström, Swethajit Biswas, Chao Chen, Joseph Cheriyan, Matthew Cleveland, Louise Cookson, Paul Galette, Robert L. Janiczek, Raymond Y. Kwong, Mary Ann Lukas, Helen Millns, Duncan Richards, Ian Schneider, Scott D. Solomon, Jens Sörensen, James Storey, Douglas Thompson, Guus van Dongen, Danielle J. Vugts, Anders Wall, Gerhard Wikström, Rodney H. Falk

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

    Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) by Magdalena Mileva, Elisabeth G. E. de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P. Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T. A. Van der Graaf, Wim J. G. Oyen, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Adrienne H. Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional I... by Christian Klein, Inja Waldhauer, Valeria G. Nicolini, Anne Freimoser-Grundschober, Tapan Nayak, Danielle J. Vugts, Claire Dunn, Marije Bolijn, Jörg Benz, Martine Stihle, Sabine Lang, Michaele Roemmele, Thomas Hofer, Erwin van Puijenbroek, David Wittig, Samuel Moser, Oliver Ast, Peter Brünker, Ingo H. Gorr, Sebastian Neumann, Maria Cristina de Vera Mudry, Heather Hinton, Flavio Crameri, Jose Saro, Stefan Evers, Christian Gerdes, Marina Bacac, Guus van Dongen, Ekkehard Moessner, Pablo Umaña

    Published 2017-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: